Dr. Jeremy Mark Gililland, MD

Dr. Gililland practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Gililland's NPI, 1881849669, was assigned on November 20, 2008. Dr. Gililland graduated from University of California, Irvine, California College of Medicine in 2007. Dr. Gililland holds Utah license 7151934-1205.

Dr. Gililland's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Gililland's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Gililland is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Gililland to 2 more hospitals, 1 group practice or clinic, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gililland practices, 6 sites in all. Vendor and product names are available with a free account.

Orthopaedic surgery is Dr. Gililland's primary specialty in the NPI Registry, under taxonomy code 207X00000X. Dr. Gililland is licensed in Utah.

CMS data shows 809 Medicare services from Dr. Gililland across 11 procedure codes in 2024, for 406 Medicare patients. Medicare paid $149,258 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 406 Medicare patients who saw Dr. Gililland in 2024. The largest group is 65 to 74, with 226 patients. 75% of them have arthritis, and 70% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gililland's median patient age at 72, with 59% women.

In 2024, Dr. Gililland wrote 122 Medicare Part D claims for 55 patients. 87% of them were for generic drugs. CMS names the drug for 84 of them, across 6 drugs with 11 or more claims each, at $1,226 in total drug cost. In 2023, CMS named 34 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Gililland for performance year 2024, reported as part of a group. Dr. Gililland accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gililland as offering telehealth. CMS counts 94 procedures of knee replacement by Dr. Gililland, more than 92% of the clinicians it reports for that procedure.

CMS Open Payments shows 943 general payments to Dr. Gililland from 18 drug and device companies from 2016 to 2025. Royalties and licenses make up the largest share, 56% of the total. Stryker Corporation paid the most, $1,749,799. It also lists 1 research payment totaling $1,035 in 2021.

Dr. Gililland graduated from University of California, Irvine, California College of Medicine in 2007.